Novavax cleared to boost Australians over 18 years Federal Novavax, the first protein-based COVID-19 vaccine to be approved by the Australian Technical Advisory Group on Immunisation (ATAGI), is now recommended for Australians 18 years
Children in Australia aged 12 and over approved for Pfizer August 27, 2021 By Melissa Coade Community & Social The Australian Technical Advisory Group on Immunisation (ATAGI) has recommended the COVID-19 mRNA vaccine Pfizer for children 12 years and over. It is the only
Aussie mRNA COVID-19 vaccine candidate moves to clinical trials August 23, 2021 By Melissa Coade Economy & Industry The arrival of a NanoAssemblr machine — a nanoparticles processor used to produce mRNA vaccines — from Canada marks another step in Australia’s mRNA vaccine
Moderna vaccine coming to Australia August 10, 2021 By Melissa Coade Federal One million doses of the mRNA COVID-19 vaccine Moderna are set to arrive in Australia next month, with the Therapeutic Goods Administration (TGA) granting provisional
Australia’s latest Pfizer vaccine delivery offers hope for rollout stuck in transit July 21, 2021 By Melissa Coade Federal Home affairs minister Karen Andrews told Australians on Monday that the arrival of almost 1 million does of the Pfizer vaccine offered a ‘light at
Possible mRNA vaccine link with heart muscle inflammation June 30, 2021 By Melissa Coade Federal Two international studies have identified a possible link between the rare incidence of heart muscle inflammation with a shot of one of the COVID-19 mRNA
Australia secures deal for further 25 million doses of Moderna vaccine May 13, 2021 By Melissa Coade Federal Australia has locked in an extra 25 million doses of the mRNA Moderna COVID-19 vaccine, the government announced on Thursday, also noting that domestic manufacturing
COVID-19 medical innovations that will outlast the pandemic March 15, 2021 By Deborah Fuller, Albert H. Titus and Nevan Krogan Editors' Picks A number of technologies and tools got a chance to prove themselves for the first time in the context of COVID-19. Three disease researchers working
